SAN JOSE, Calif., May 7, 2026 – For patients in their 70s and 80s managing macular disease, the assumption has been that at-home digital monitoring won't stick. A year of real-world data from Stanford Health Care just changed that. Twelve-month results from a consecutive case series led by Theodore Leng, MD, MS, of the Byers Eye Institute at Stanford University School of Medicine are being presented today at ARVO 2026.
Stanford Health Care patients were prescribed the myVisionTrack (mVT) app — a Class I Software as a Medical Device (SaMD) developed at the direction of a global pharmaceutical company and built on BrightInsight's platform. mVT enables at-home vision testing between clinic visits, using shape discrimination hyperacuity (SDH) to detect changes before the next scheduled appointment.
The year-long results told a different story than those of most digital health programs. The drop-off didn't materialize. Instead, patient engagement deepened, with reminder adoption increasing and monthly testing rates holding steady through year's end.
Key findings:
The Stanford Health Care program enrolled 118 patients across a range of macular diagnoses — intermediate AMD, geographic atrophy, neovascular AMD, diabetic macular edema, retinal vein occlusion and epiretinal membrane. The primary drop-off occurred early: of 73 patients who received an mVT prescription, 56 completed registration, and 47 went on to complete their first test. Patients who cleared that initial threshold kept testing.
The demographic profile underscores the findings. The median age of active mVT app users was 74, with the largest single cohort aged 76–80. Most completed bilateral testing — both eyes — in under five minutes, on their own devices.
"What surprised us wasn't that patients tested their vision with mVT — it was that they didn't stop. For a population with a median age of 74 managing serious retinal disease, that level of sustained engagement challenges what most of us assumed was possible with home monitoring." — Theodore Leng, MD, MS, Byers Eye Institute at Stanford University School of Medicine
The data points to something BrightInsight has observed across its platform: getting patients to start — and stay on — life-changing therapy requires more than a prescription. Keeping them engaged is a design problem, not a patient problem.
"The Stanford data closes the argument about whether patients in this population will use a tool like this. They will. The question now is whether the rest of the field catches up." — Kal Patel, MD, CEO and Co-Founder, BrightInsight
About BrightInsight
BrightInsight is the patient persistence solution for the world's top pharma and biotech companies. BrightInsight helps patients start — and stay on — life-changing therapy by detecting the behavioral signals that precede drop-off and intervening before discontinuation becomes a decision. Built to scale globally with the compliance infrastructure that regulated markets demand, BrightInsight is the foundation global biopharma brands rely on to realize the full value of their therapies. For more details, visit BrightInsight’s website, Blog, and LinkedIn pages.
Media Contact
Nicole Warshauer
VP of Marketing, BrightInsight
nicole.warshauer@brightinsight.com